- Previous Close
19.49 - Open
19.54 - Bid 20.05 x 100
- Ask 20.17 x 100
- Day's Range
19.24 - 20.31 - 52 Week Range
17.05 - 39.83 - Volume
265,879 - Avg. Volume
1,048,015 - Market Cap (intraday)
2.507B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-4.65 - Earnings Date Nov 27, 2024 - Dec 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.29
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
arrowheadpharma.comRecent News: ARWR
View More
Performance Overview: ARWR
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARWR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARWR
View MoreValuation Measures
Market Cap
2.42B
Enterprise Value
2.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
114.57
Price/Book (mrq)
7.33
Enterprise Value/Revenue
107.21
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.72%
Return on Equity (ttm)
-151.84%
Revenue (ttm)
19.65M
Net Income Avi to Common (ttm)
-538.64M
Diluted EPS (ttm)
-4.65
Balance Sheet and Cash Flow
Total Cash (mrq)
434.47M
Total Debt/Equity (mrq)
133.97%
Levered Free Cash Flow (ttm)
-413.91M
Research Analysis: ARWR
View MoreCompany Insights: ARWR
ARWR does not have Company Insights
Research Reports: ARWR
View MoreWhat does Argus have to say about ARWR?
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about ARWR?
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $21.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $19.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target